New oral drug for active ulcerative colitis
Part of Digestive system clinical trials.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ulcerative colitis for at least 12 weeks.
- Your disease should be moderately active, as confirmed by a colonoscopy.
- You must have tried at least one standard UC treatment (like mesalamine, steroids, or azathioprine) and it didn't work well enough or caused side effects.
- You cannot have severe UC requiring hospitalization or surgery.
- You cannot have certain other bowel conditions (like Crohn's disease, microscopic colitis, or a history of colonic dysplasia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
This study tests an investigational pill (PTT-621) for moderate to severe ulcerative colitis that hasn't responded well to standard treatments. It aims to see if the drug can reduce inflammation and improve symptoms, while checking safety and how the body handles it.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.